Assessment of HER2 status in breast cancer: why, when and how? (Q33877899)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

Assessment of HER2 status in breast cancer: why, when and how? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

M Dowsett

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

T Cooke

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

W J Gullick

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

B Gusterson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

E Mallon

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

R Walker

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

170-176

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

Specificity within the EGF family/ErbB receptor family signaling network

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Receptor protein-tyrosine kinases and their signal transduction pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

The biology of erbB-2/neu/HER-2 and its role in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Quantitative radioimmunohistochemical measurements of p185(erbB-2) in frozen tissue sections

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

The HercepTest assay: another perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Overexpression of the c-erbB-2 protein in human breast tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900264-6

7 January 2021

10.1016/S0959-8049(99)00264-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741274%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference